KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

被引：0
|
作者：
F Loupakis
A Ruzzo
C Cremolini
B Vincenzi
L Salvatore
D Santini
G Masi
I Stasi
E Canestrari
E Rulli
I Floriani
K Bencardino
N Galluccio
V Catalano
G Tonini
M Magnani
G Fontanini
F Basolo
A Falcone
F Graziano
机构：
[1] Unit of Medical Oncology 2,Istituto Toscano Tumori and Department of Oncology
[2] Azienda-Ospedaliero Universitaria Pisana,Department of Biomolecular Sciences
[3] Transplantes and New Technologies in Medicine,Division of Pathology, Department of Surgery
[4] University of Pisa,undefined
[5] Section of Biochemistry and Molecular Biology “G. Fornaini”,undefined
[6] University of Urbino,undefined
[7] Unit of Medical Oncology,undefined
[8] University Campus Biomedico,undefined
[9] Via Alvaro del Portillo 200 – 00128 Rome,undefined
[10] Italy,undefined
[11] Mario Negri Institute for Pharmacological Research,undefined
[12] Via La Masa 19 – 20156 Milan,undefined
[13] Italy,undefined
[14] Unit of Medical Oncology,undefined
[15] San Raffaele Scientific Institute,undefined
[16] Via Olgettina 60 – 20132 Milan,undefined
[17] Italy,undefined
[18] Unit of Medical Oncology,undefined
[19] Hospital of Pesaro,undefined
[20] Via Lombroso 1 – 61100 Pesaro,undefined
[21] Italy,undefined
[22] University of Pisa,undefined
[23] Istituto Toscano Tumori,undefined
[24] Via Roma 67 – Pisa,undefined
[25] Italy,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：715 / 721
页数：6
相关论文
共 50 条
  • [1] KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    Loupakis, F.
    Ruzzo, A.
    Cremolini, C.
    Vincenzi, B.
    Salvatore, L.
    Santini, D.
    Masi, G.
    Stasi, I.
    Canestrari, E.
    Rulli, E.
    Floriani, I.
    Bencardino, K.
    Galluccio, N.
    Catalano, V.
    Tonini, G.
    Magnani, M.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    Graziano, F.
    BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 715 - 721
  • [2] KRAS CODON 61, 146 AND BRAF V600E MUTATIONS PREDICT RESISTANCE TO CETUXIMAB PLUS IRINOTECAN IN KRAS CODON 12 AND 13 WILD-TYPE METASTATIC COLORECTAL CANCER
    Ruzzo, Annamaria
    Loupakis, Fotios
    Canestrari, Emanuele
    Cremolini, Chiara
    Vincenzi, Bruno
    Salvatore, Lisa
    Santini, Daniele
    Masi, Gianluca
    Stasi, Irene
    Rulli, Eliana
    Floriani, Irene
    Bencardino, Katia
    Galluccio, Nadia
    D'Emidio, Silvia
    Catalano, Vincenzo
    Tonini, Giuseppe
    Magnani, Mauro
    Falcone, Alfredo
    Graziano, Francesco
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] CLINICAL OUTCOME OF CETUXIMAB FOR METASTATIC COLORECTAL CANCER PATIENTS HARBORING KRAS CODON61, KRAS CODON146, BRAF, NRAS OR PIK3CA MUTATIONS
    Shinozaki, E.
    Bando, H.
    Nishina, T.
    Yamazaki, K.
    Kadowaki, S.
    Yuki, S.
    Kajiura, S.
    Tsuchihara, K.
    Fujii, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 196 - 197
  • [4] CLINICAL OUTCOME OF CETUXIMAB FOR METASTATIC COLORECTAL CANCER PATIENTS HARBORING KRAS CODON61, KRAS CODON146, BRAF, NRAS OR PIK3CA MUTATIONS
    Yamazaki, K.
    Bando, H.
    Shinozaki, E.
    Nishina, T.
    Kadowaki, S.
    Yuki, S.
    Kajiura, S.
    Tsuchihara, K.
    Fujii, S.
    Yamanaka, T.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [5] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [6] Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
    Liang, Yi-Hsin
    Lin, Yu-Lin
    Liau, Jau-Yu
    Tsai, Jia-Huei
    Liang, Jin-Tung
    Lin, Been-Ren
    Hung, Ji-Shiang
    Tseng, Li-Hui
    Lin, Liang-In
    Chang, Yih-Leong
    Cheng, Ann-Lii
    Yeh, Kun-Huei
    ANTICANCER RESEARCH, 2015, 35 (07) : 4207 - 4214
  • [7] Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
    Hsu, Hung-Chih
    Thiam, Tan Kien
    Lu, Yen-Jung
    Yeh, Chien Yuh
    Tsai, Wen-Sy
    You, Jeng Fu
    Hung, Hsin Yuan
    Tsai, Chi-Neu
    Hsu, An
    Chen, Hua-Chien
    Chen, Shu-Jen
    Yang, Tsai Sheng
    ONCOTARGET, 2016, 7 (16) : 22257 - 22270
  • [8] Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer
    Shitara, Kohei
    Ura, Takashi
    Matsuo, Keitaro
    Takahari, Daisuke
    Yokota, Tomoya
    Yuki, Satoshi
    Yoshida, Motoki
    Utsunomiya, Setsuo
    Sato, Yozo
    Yamaura, Hidekazu
    Kato, Mina
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (18) : 2673 - 2680
  • [9] Recurrent KRAS Codon 146 mutations in human colorectal cancer
    Edkins, Sarah
    O'Meara, Sarah
    Parker, Adrian
    Stevens, Claire
    Reis, Marcelo
    Jones, Sian
    Greenman, Chris
    Davies, Helen
    Dalgliesh, Gillian
    Forbes, Simon
    Hunter, Chris
    Smith, Raffaella
    Stephens, Philip
    Goldstraw, Peter
    Nicholson, Andrew
    Chan, Tsun Leung
    Velculescu, Victor E.
    Yuen, Siu Tsan
    Leung, Suet Yi
    Stration, Michael R.
    Futreal, P. Andrew
    CANCER BIOLOGY & THERAPY, 2006, 5 (08) : 928 - 932
  • [10] KRAS Codon 12, 13, 61 and 146 Mutations in 1267 Colorectal Cancers: Clinicopathological, Molecular, and Survival Analyses
    Liao, X.
    Imamura, Y.
    Ogino, S.
    LABORATORY INVESTIGATION, 2013, 93 : 165A - 165A
12345